nct_id: NCT06699771
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-11-21'
study_start_date: '2025-03-07'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: GCC2005'
  - drug_name: 'Drug: Fludarabine'
  - drug_name: 'Drug: Cyclophosphamide'
long_title: A Phase 1, Multicenter Trial to Assess the Safety, Tolerability, and Preliminary
  Efficacy of GCC2005 With Lymphodepleting Chemotherapy in Treatment of Patients With
  Relapsed or Refractory NK and T-cell Malignancies
last_updated: '2025-04-30'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: GC Cell Corporation
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 48
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Patients with relapsed or refractory CD5+ NK and T-cell originated malignancies
  (per WHO classification 2017).'
- '* Patients with relapsed or refractory disease previously treated with two or more
  lines of standard chemotherapies and there is no longer any treatment option considered
  as assessed by the Investigator.'
- "* According to the Lugano classification, patients having lesion/nodules \u2265\
  \ 1 with diameter longer than 1.5 cm for nodal lesions and longer than 1.0 cm for\
  \ extranodal lesions, and the boundaries are clearly shown."
- '* Patient has a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology
  Group (ECOG) Performance Status.'
- '* Patients who satisfy the criteria defined in the protocol.'
- '* Contraceptive use by men and women must be consistent with local regulations
  regarding the methods of contraception for those participating in clinical studies.'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Has T-ALL/T-LBL or CTCL.
- Exclude - * Patient with CNS lymphoma or any involvement of the CNS.
- Exclude - * Patient who had a prior history of another malignancy over the last
  3 years.
- Exclude - * Patients who have used hematopoietic growth factor therapy within 14
  days prior to Screening.
- Exclude - * Patients who have had prior CAR-T or CAR-NK therapies.
- Exclude - * Presence of uncontrolled fungal, bacterial, viral infection or other
  infection requiring IV antimicrobials for management
- Exclude - * Patients with previous allogenic organ transplantation
- Exclude - * Patients with previous diagnosis of primary immunodeficiency or currently
  undergoing therapy of primary immunodeficiency.
- "Exclude - * Patients with acute GvHD \u2265 Grade 3 or extensive chronic GvHD within\
  \ 2 weeks of lymphodepletion."
- Exclude - * Patients with known active Hepatitis B or C
- Exclude - * Patients with presence of Grade 2 or greater toxicity from the previous
  treatment.
short_title: Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005
  in Patients With R/R NK and T-cell Malignancies
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: GC Cell Corporation
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This is a Phase 1 (a and b), first in human (FIH), single-arm, open-label,
  multicenter study to evaluate the safety, tolerability and efficacy of GCC2005 in
  the treatment of patients with relapsed/refractory (R/R) NK or T-cell malignancies
  who have received at least two prior lines of therapy.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Phase 1a Dose Escalation and Phase 1b Dose Expansion
      arm_internal_id: 0
      arm_description: Dose Confirmation of GCC2005 in Relapsed or Refractory NK and
        T-cell Malignancies
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: GCC2005'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Cyclophosphamide'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Fludarabine'
        level_internal_id: 2
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=19'
        disease_status:
        - Recurrent
        - Refractory
        oncotree_primary_diagnosis: Lymphoid Neoplasm
